Explore the Agenda
8:00 am Check in & Light Breakfast
8:55 am Chair’s Opening Remarks
Unlocking New Frontiers in Autoimmune Disease Through Precision Target Discovery & Immune Modulation to Enable Next-Generation Therapies
9:00 am Next-Generation Autoimmune Therapeutics: Controlled Immune Tolerance Restorer & B/Plasma Cell-depleting OR-Gated T-Cell Engager
- ATG-207 is a first-in-class immune tolerance-inducing biologic that integrates three key design elements: 1) CD3-mediated targeting, which localizes the molecule to T cells; 2) a conformationally dynamic masking mechanism, which reduces systemic TGF-B activity; and 3) TGFBRIII-biased signaling, which further enhances selectivity toward T cells
- ATG-207 leads to coordinated immune tolerance induction – promotion of Treg differentiation and controlled attenuation of pathogenic T cell activityATG-203 is a trispecific T-cell engager, leveraging Antengene proprietary OR-gated TriGagerTM platform, which enables a broad patient coverage across CD19+ pathogenic B cell population as well the plasmablast transition zone
9:30 am Unlocking Novel Autoimmune Therapeutic Opportunities Through Precision Peptide-HLA Target Discovery & Immune Modulation
- Leveraging advanced peptide-HLA discovery platforms to identify disease-driving antigens and previously inaccessible targets, expanding the range of therapeutic opportunities beyond conventional immune-cell surface markers
- Exploring multiple strategies for selectively targeting peptide-HLA complexes, including T-cell engagers and other precision immune-modulating approaches, to enhance specificity while minimizing off-target immune effects
- Presenting case studies highlighting the discovery, validation, and therapeutic potential of novel peptide-HLA targets, demonstrating how precision antigen recognition can enable the next generation of autoimmune disease therapies
10:00 am Roundtable Discussion: Identifying the Most Promising Precision Targets to Shape the Next Generation of Autoimmune T-Cell Engagers
As autoimmune T-cell engager development moves beyond first-generation approaches, the field is increasingly focused on identifying which immune-cell populations and biological pathways will deliver the safest, most selective, and most durable therapeutic responses.
In this interactive roundtable session, attendees will break into smaller discussion groups to evaluate the opportunities, challenges, and translational considerations associated with three of the most important target classes shaping the future of autoimmune T-cell engager development. Each group will discuss one of the following areas:
- Broad B-cell lineage markers, exploring the advantages and limitations of targeting widely expressed B-cell populations to achieve deep immune-cell depletion, rapid disease control, and scalable therapeutic applicability across multiple autoimmune indications
- Plasma cell reservoirs, discussing strategies to eliminate long-lived pathogenic plasma cells that may drive chronic disease persistence and relapse, while balancing infection risk, immune preservation, and long-term safety considerations
- Autoreactive antigen-specific B cells, evaluating emerging precision approaches designed to selectively target diseasedriving immune-cell populations while minimizing off-target immune depletion and preserving broader immune competence
10:30 am Morning Break & Networking
11:00 am Advancing CD8-Biased T-Cell Engagers to Enhance Precision Immune Modulation & Improve Safety in Autoimmune Disease
- Developing next-generation CD8-biased T-cell engager platforms targeting B cells, plasma cells, and broader immune biology to achieve potent and selective immunecell depletion while minimizing excessive immune activation
- Evaluating how CD8-biased engagement strategies may reduce cytokine release and lower cytokine release syndrome risk while retaining strong in vitro potency, leveraging translational data generated from cytokine release assays, healthy donor studies, and patient-derived immune-cell samples
- Presenting emerging insights from AstraZeneca’s externally disclosed autoimmune T-cell engager programs, including the CD20-targeting molecule “5492,” to demonstrate how precision immune modulation and differentiated safety profiles may support competitive positioning within an increasingly crowded therapeutic landscape
11:30 am Panel Discussion: Unlocking Precision Immune Targeting to Move Beyond Broad Immune Cell Depletion in Autoimmune Disease
The first generation of autoimmune T-cell engagers has demonstrated the power of broad immune-cell depletion, but questions remain around how to achieve deeper, more durable responses while minimizing infection risk, preserving protective immunity, and addressing disease heterogeneity. The next wave of innovation is focused on identifying diseasedriving immune cells, novel targets, and precision immune modulation strategies capable of delivering more selective and effective therapies. Explore how the field can move beyond conventional approaches by:
- Identifying the optimal pathogenic immune-cell populations to target, evaluating advances in target discovery, immune repertoire profiling, and disease biology to distinguish disease-driving cells from healthy immune populations and improve therapeutic selectivity
- Advancing multi-specific and precision immune modulation strategies, discussing how trispecific, logic-gated, and nextgeneration immune engager platforms can enhance specificity, overcome antigen heterogeneity, and deliver deeper and more durable disease control
- Balancing efficacy, safety, and immune preservation, exploring how novel targeting approaches can achieve potent depletion of pathogenic cells while minimizing off-target toxicity, reducing infection risk, and preserving long-term immune competence
Advancing Safer T-Cell Engager Therapies Through Improved Toxicity Management & Precision Design to Expand the Therapeutic Window
12:00 pm Leveraging Novel T-Cell Engagement Mechanisms to Expand the Therapeutic Window Through Improved Precision, Safety & Immune Modulation
- Developing a differentiated mechanism of action that redirects and amplifies endogenous immune signalling pathways to drive potent T-cell activity while reducing excessive immune activation and treatment-related toxicity
- Demonstrating an improved therapeutic window in non-human primate models through enhanced efficacy, controlled cytokine release, and improved tolerability, supporting the potential for safer clinical application across autoimmune disease settings
- Exploring how precision immune-modulatory approaches can be applied across both oncology and autoimmune indications, leveraging shared mechanistic insights to optimize efficacy, safety management, and long-term therapeutic benefit
12:30 pm Lunch & Networking
1:30 pm Leveraging Precision Antigen Discovery & Novel CD3 Bispecific Design to Enable Safer B-Cell Depletion in Autoimmune Disease
- Utilizing the T-Ca platform to identify disease-driving antigens and pathogenic immune-cell populations, enabling the development of highly selective therapies that minimize off-target immune depletion and improve therapeutic precision
- Translating a CD3 bispecific platform originally developed for oncology into autoimmune disease, applying established insights into target engagement, immunecell depletion, and safety management to accelerate clinical development
- Integrating translational biology and patient-derived immune profiling to optimize target selection, improve benefit-risk profiles, and deliver more effective and durable outcomes for patients with autoimmune disease
2:00 pm Panel Discussion: Harnessing Co-Stimulation to Enhance T-Cell Persistence, Overcome Exhaustion & Unlock Durable Autoimmune Responses
As autoimmune T-cell engagers move beyond first-generation designs, many developers are encountering a common challenge, exhausted and dysfunctional T cells may limit the depth and durability of clinical responses. Co-stimulatory approaches have emerged as a promising strategy to enhance T-cell fitness, persistence, and efficacy, but questions remain around how much co-stimulation is needed and how to balance improved potency with cytokine release and safety risks.
This panel will discuss how co-stimulation could reshape the future of autoimmune therapy by:
- Understanding the biology of T-cell exhaustion and persistence, exploring the mechanisms driving reduced T-cell functionality in autoimmune patients and identifying opportunities to restore effective immune responses
- Evaluating emerging co-stimulatory strategies, comparing approaches leveraging CD28, CD2, 4 1BB, and other pathways to determine how they influence efficacy, durability, immune-cell depletion, and safety profiles
- Defining the optimal balance between potency and safety, discussing how co-stimulation can be integrated into nextgeneration engager designs to maximize clinical benefit while minimizing cytokine release syndrome, off-target activation, and long-term immune suppression
2:30 pm Optimizing Multi-Targeted Immune Cell Depletion with FP014 to Enhance Therapeutic Window, Efficacy & Long-Term Disease Control
- Evaluating how simultaneous targeting of multiple B-cell populations through a trispecific approach can improve the depth and consistency of immune-cell depletion while reducing the risk of disease persistence and target escape
- Characterizing the relationship between target engagement, cytokine release, immune-cell depletion kinetics, and safety outcomes to identify strategies that maximize therapeutic benefit while minimizing toxicity
- Leveraging de novo engineered T-cell toolbox and platform to enable faster and safer deployment of next generation TCE molecules in autoimmune disease
Defining the Future Competitive Landscape of Autoimmune T-Cell Engagers Through Clinical Differentiation, Regulatory Strategy & Commercial Positioning
3:00 pm Panel Discussion: Demonstrating Differentiation in a Crowded Autoimmune TCE Landscape While Navigating an Evolving Regulatory Pathway
As the autoimmune T-cell engager field rapidly expands, developers face increasing pressure to demonstrate meaningful differentiation beyond simply being first to market. At the same time, regulators are grappling with how to evaluate therapies originally developed for oncology in patient populations with fundamentally different risk-benefit expectations. The challenge is no longer just proving activity, it is demonstrating why a therapy deserves adoption, investment, and regulatory approval in an increasingly competitive market.
Join biotech innovators, regulatory experts, clinical developers, and investors as they discuss how companies can successfully position their programs for both commercial and regulatory success by:
- Defining meaningful differentiation beyond target selection, exploring how developers can distinguish their therapies through safety profiles, depth and durability of response, patient convenience, biomarker strategies, co-stimulatory approaches, and disease-specific mechanisms rather than relying solely on novel targets
- Aligning development strategies with evolving regulatory expectations, discussing how regulators are approaching autoimmune T-cell engagers differently from oncology therapies, including considerations around toxicology requirements, cytokine release syndrome risk, chronic safety monitoring, and benefit-risk assessment
- Designing clinical programs that support both approval and competitive positioning, evaluating which endpoints, biomarkers, patient populations, and clinical datasets will be most important for demonstrating value to regulators, physicians, payers, and potential partners in an increasingly crowded field